Finance

Lists
BLFS:NASDAQ
BioLife Solutions Inc
$35.38
+0.37%
(+0.13) 1D
$35.38
0.00% (0.00)
After hours
Closed: Sep 8, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLFS...
Open
$35.03
High
$36.06
Low
$35.03
Mkt. cap
1.73B
Avg. vol.
778.34K
Volume
788.40K
P/E ratio
29.94
52-wk high
$38.10
52-wk low
$17.86
EPS
$1.18
Beta
1.92
Shares outstanding
48.91M
No. of employees
155
Open
$35.03
High
$36.06
Low
$35.03
Mkt. cap
1.73B
Avg. vol.
778.34K
Volume
788.40K
P/E ratio
29.94
52-wk high
$38.10
52-wk low
$17.86
EPS
$1.18
Beta
1.92
Shares outstanding
48.91M
No. of employees
155
News stories
From web sources and news partners
About BioLife Solutions Inc
CEO-
Employees155
Founded1987
HeadquartersBothell, Washington, United States
SectorHealth care
Websitebiolifesolutions.com
Analyst ratings
Based on 8 analysts giving stock ratings to BLFS in the past 3 months
Hold
Buy
0
Hold
8
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for BLFS in the last 3 months.
Highest
Current $35.38
$31.00 (-12.38%)
Average
$31.00 (-12.38%)
Lowest
$31.00 (-12.38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Wasserman
Benchmark Co.
Hold
Downgraded
-
-
08/10/2026
Brendan Smith
TD Cowen
Hold
Maintained
$31.00
-12.4%
08/07/2026
Thomas Flaten
Lake Street
Hold
Maintained
$31.00
-12.4%
08/07/2026
Steven Etoch
Stephens
Hold
Downgraded
$31.00
-12.4%
07/27/2026
Matthew Stanton, CFA
Jefferies
Hold
Downgraded
$31.00
-12.4%
07/23/2026
Yi Chen
H.C. Wainwright
Hold
Downgraded
$31.00
-12.4%
07/23/2026
Matt Hewitt
Craig-Hallum
Hold
Downgraded
$31.00
-12.4%
07/22/2026
Jason McCarthy
Maxim Group
Hold
Downgraded
-
-
07/23/2026
Carl Byrnes
Northland Securities
Buy
Reiterated
$34.00
-3.9%
03/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
28.07M
24.76M
27.50M
28.47M
Cost of goods sold
10.15M
9.25M
10.00M
10.18M
Cost of revenue
10.15M
9.25M
10.00M
10.18M
Research and development expenses
2.71M
2.07M
2.65M
2.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.60M
13.46M
14.73M
13.48M
Operating expense
18.01M
15.60M
17.47M
16.59M
Total operating expenses
28.16M
24.84M
27.47M
26.77M
Operating income
-89.00K
-80.00K
27.00K
1.70M
Other non operating income
284.00K
1.18M
58.00K
63.00K
EBT including unusual items
703.00K
1.94M
1.25M
2.75M
EBT excluding unusual items
703.00K
1.94M
1.13M
2.75M
Income tax expense
82.00K
-173.00K
62.00K
-42.35M
Effective tax rate
11.66%
-8.94%
4.97%
-1,538.36%
Other operating expenses
-
-
-
-
Net income
621.00K
11.07M
1.19M
45.10M
Net profit margin
2.21%
44.70%
4.31%
158.45%
Earnings per share
0.04
0.04
0.04
0.08
Interest and investment income
508.00K
831.00K
1.04M
994.00K
Interest expense
-
-
-
-
Net interest expenses
508.00K
831.00K
1.04M
994.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
1.25M
506.00K
726.00K
2.50M
Gain or loss from assets sale
167.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps